Exploratory Study on the Efficacy of Bortezomib Combining Mitoxantrone or CD22-CAR T Therapy Targeting CD19-Negative Relapse After CD19-CAR T Cell Therapy With a Simpler Cell-Line-Based Model

Investigators established a cellular model system using a CD19-positive B lineage acute lymphoblastic leukemia (B-ALL) cell line Nalm-6 to investigate the treatment options for CD19-negative relapsed B-ALL after CD19-CAR T cell therapy.